{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"12.4","value":"73.5"},{"groupId":"OG001","value":"87.7"},{"groupId":"OG002","spread":"9.24","value":"45.3"},{"groupId":"OG003","spread":"71.4","value":"142.00"},{"groupId":"OG004","spread":"67.2","value":"158.0"},{"groupId":"OG005","spread":"43.1","value":"186.0"},{"groupId":"OG006","spread":"83.1","value":"257.0"},{"groupId":"OG007","spread":"120.0","value":"186.0"},{"groupId":"OG008","spread":"131.0","value":"295.0"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"1"},{"groupId":"OG002","value":"3"},{"groupId":"OG003","value":"7"},{"groupId":"OG004","value":"6"},{"groupId":"OG005","value":"6"},{"groupId":"OG006","value":"7"},{"groupId":"OG007","value":"7"},{"groupId":"OG008","value":"6"}],"units":"Participants"}],"dispersionType":"Standard Deviation","groups":[{"description":"Participants (in fasting condition) received single dose of 20 or 40 mg alectinib capsules orally to make a dose of 240 mg on Cycle 1 Day -3 and then received 300 mg BID dose for 3-weekly cycles until disease progression, death or withdrawal for any other reasons.","id":"OG000","title":"Alectinib 240 mg Once and 300 mg BID (Fasted): Phase I"},{"description":"Participants (in non-fasting condition) received single dose of 20 or 40 mg alectinib capsules orally to make a dose of 240 mg on Cycle 1 Day -3 and then received 300 mg BID dose for 3-weekly cycles until disease progression, death or withdrawal for any other reasons.","id":"OG001","title":"Alectinib 240 mg Once and 300 mg BID (Fed): Phase I"},{"description":"Participants received single dose of 20 or 40 mg alectinib capsules orally to make a dose of 300 mg on Cycle 1 Day -3 and then received 300 mg BID dose for 3-weekly cycles until disease progression, death or withdrawal for any other reasons.","id":"OG002","title":"Alectinib 300 mg (Fasted): Phase I"},{"description":"Participants received single dose of 20 or 40 mg alectinib capsules orally to make a dose of 460 mg on Cycle 1 Day -3 and then received 460 mg BID dose for 3-weekly cycles until disease progression, death or withdrawal for any other reasons.","id":"OG003","title":"Alectinib 460 mg (Fed): Phase I"},{"description":"Participants received single dose of 20 or 40 mg alectinib capsules orally to make a dose of 600 mg on Cycle 1 Day -3 and then received 600 mg BID dose for 3-weekly cycles until disease progression, death or withdrawal for any other reasons.","id":"OG004","title":"Alectinib 600 mg (Fed): Phase I (20/40 mg)"},{"description":"Participants received single dose of 150 mg alectinib capsules orally to make a dose of 600 mg on Cycle 1 Day -3 and then received 600 mg BID dose for 3-weekly cycles until disease progression, death or withdrawal for any other reasons.","id":"OG005","title":"Alectinib 600 mg (Fed): Phase I (150 mg)"},{"description":"Participants received single dose of 20 or 40 mg alectinib capsules orally to make a dose of 760 mg on Cycle 1 Day -3 and then received 760 mg BID dose for 3-weekly cycles until disease progression, death or withdrawal for any other reasons.","id":"OG006","title":"Alectinib 760 mg (Fed): Phase I"},{"description":"Participants received single dose of 20 or 40 mg alectinib capsules orally to make a dose of 900 mg on Cycle 1 Day -3 and then received 900 mg BID dose for 3-weekly cycles until disease progression, death or withdrawal for any other reasons.","id":"OG007","title":"Alectinib 900 mg (Fed): Phase I (20/40 mg)"},{"description":"Participants received single dose of 150 mg alectinib capsules orally to make a dose of 900 mg on Cycle 1 Day -3 and then received 900 mg BID for 3-weekly cycles until disease progression, death or withdrawal for any other reasons.","id":"OG008","title":"Alectinib 900 mg (Fed): Phase I (150 mg)"}],"paramType":"MEAN","populationDescription":"Phase I pharmacokinetic (PK) evaluable population included all participants who received any dose of alectinib and who had at least one post-baseline PK sample available. 'Overall Number of Participants Analyzed' = participants evaluable for this outcome measure.","reportingStatus":"POSTED","timeFrame":"Pre-dose (0 hour), 0.5, 1, 2, 4, 6, 8, 10, 24, 32 and 48 hours post-dose on Cycle 1 Day -3 (1 cycle = 21 days)","title":"Maximum Observed Plasma Concentration (Cmax) After Single Dose of Alectinib: Phase I","type":"SECONDARY","unitOfMeasure":"nanograms per milliliter (ng/mL)"}